Lupin Pharmaceuticals, Inc.’s Abbreviated New Drug Application (ANDA) for its Cefdinir Capsules, 300 mg has been granted final approval by the USFDA.
Cefdinir Capsules, an extended-spectrum semisynthetic cephalosporin used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria, is the AB-rated generic equivalent of Abbott Laboratories' Omnicef® Capsules.
Lupin Pharmaceuticals, Inc., a U.S. wholly owned subsidiary of Lupin Limited (one of the top 6 Pharmaceutical companies in India), with its sales and marketing headquarters in Baltimore, Maryland, is dedicated to delivering high-quality, affordable generic medicines trusted by healthcare professionals and patients across geographies.
Source: PR Newswire
Comment Preview